These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 37000300)
1. Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong. Mui JV; Li L; Chou OHI; Azfar N; Lee A; Hui J; Lee S; Tse G; Zhou J Acta Diabetol; 2023 Jul; 60(7):917-927. PubMed ID: 37000300 [TBL] [Abstract][Full Text] [Related]
2. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong. Lee S; Zhou J; Leung KSK; Wai AKC; Jeevaratnam K; King E; Liu T; Wong WT; Chang C; Wong ICK; Cheung BMY; Tse G; Zhang Q Cardiovasc Drugs Ther; 2023 Jun; 37(3):561-569. PubMed ID: 35142921 [TBL] [Abstract][Full Text] [Related]
3. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users. Zhou J; Lee S; Leung KSK; Wai AKC; Liu T; Liu Y; Chang D; Wong WT; Wong ICK; Cheung BMY; Zhang Q; Tse G ESC Heart Fail; 2022 Apr; 9(2):1388-1399. PubMed ID: 35132823 [TBL] [Abstract][Full Text] [Related]
4. New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study. Gao X; Zhang N; Lu L; Gao T; Chou OHI; Wong WT; Chang C; Wai AKC; Lip GYH; Zhang Q; Tse G; Liu T; Zhou J Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):103-117. PubMed ID: 37962962 [TBL] [Abstract][Full Text] [Related]
5. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong. Au PCM; Tan KCB; Lam DCL; Cheung BMY; Wong ICK; Kwok WC; Sing CW; Cheung CL JAMA Netw Open; 2023 Jan; 6(1):e2251177. PubMed ID: 36648944 [TBL] [Abstract][Full Text] [Related]
6. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes. Zhou J; Liu X; Chou OH; Li L; Lee S; Wong WT; Zhang Q; Chang C; Liu T; Tse G; Jing F; Cheung BMY Rheumatology (Oxford); 2023 Apr; 62(4):1501-1510. PubMed ID: 36066415 [TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study. Chou OHI; Chauhan VK; Chung CTS; Lu L; Lee TTL; Ng ZMW; Wang KKW; Lee S; Liu H; Pang RTK; Kaewdech A; Cheung BMY; Tse G; Zhou J Gastric Cancer; 2024 Sep; 27(5):947-970. PubMed ID: 38856768 [TBL] [Abstract][Full Text] [Related]
8. Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in Type 2 diabetes mellitus: A population-based study. Chung CT; Lakhani I; Chou OHI; Lee TTL; Dee EC; Ng K; Wong WT; Liu T; Lee S; Zhang Q; Cheung BMY; Tse G; Zhou J Cancer Med; 2023 Jun; 12(11):12299-12315. PubMed ID: 37148547 [TBL] [Abstract][Full Text] [Related]
9. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study. Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074 [TBL] [Abstract][Full Text] [Related]
10. Lower Risks of New-Onset Hepatocellular Carcinoma in Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors Versus DPP4 Inhibitors. Chou OHI; Ning J; Chan RNC; Chung CT; Huang H; Ng K; Dee EC; Lee S; Kaewdech A; Chow AKM; Man NK; Liu T; Jing F; Cheung BMY; Tse G; Zhou J J Natl Compr Canc Netw; 2024 Jun; 22(2 D):. PubMed ID: 38862004 [TBL] [Abstract][Full Text] [Related]
11. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436 [TBL] [Abstract][Full Text] [Related]
12. Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes. Richardson TL; Halvorson AE; Hackstadt AJ; Hung AM; Greevy R; Grijalva CG; Elasy TA; Roumie CL Ann Intern Med; 2023 Jun; 176(6):751-760. PubMed ID: 37155984 [TBL] [Abstract][Full Text] [Related]
13. Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor. Chan YH; Chao TF; Chen SW; Kao YW; Huang CY; Chu PH Eur Heart J Qual Care Clin Outcomes; 2023 Jun; 9(4):397-407. PubMed ID: 35797996 [TBL] [Abstract][Full Text] [Related]
14. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis. Mui JV; Zhou J; Lee S; Leung KSK; Lee TTL; Chou OHI; Tsang SL; Wai AKC; Liu T; Wong WT; Chang C; Tse G; Zhang Q Front Cardiovasc Med; 2021; 8():747620. PubMed ID: 34746262 [No Abstract] [Full Text] [Related]
15. Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan. Kashiwagi A; Shoji S; Kosakai Y; Koga T; Asakawa K; Rokuda M J Diabetes Investig; 2023 Mar; 14(3):404-416. PubMed ID: 36515129 [TBL] [Abstract][Full Text] [Related]
16. Fracture risks associated with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients across eGFR and albuminuria categories: A population-based study in Hong Kong. Lui DTW; Wu T; Tang EHM; Au ICH; Lee CH; Woo YC; Tan KCB; Wong CKH Diabetes Res Clin Pract; 2023 Mar; 197():110576. PubMed ID: 36780955 [TBL] [Abstract][Full Text] [Related]
17. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis. Min SH; Yoon JH; Moon SJ; Hahn S; Cho YM Sci Rep; 2018 Mar; 8(1):4466. PubMed ID: 29535389 [TBL] [Abstract][Full Text] [Related]
18. Comparisons of the risks of new-onset prostate cancer in type 2 diabetes mellitus between SGLT2I and DPP4I users: A population-based cohort study. Chou OHI; Lu L; Chung CT; Chan JSK; Chan RNC; Lee AYH; Dee EC; Ng K; Pui HHH; Lee S; Cheung BMY; Tse G; Zhou J Diabetes Metab; 2024 Aug; 51(1):101571. PubMed ID: 39182669 [TBL] [Abstract][Full Text] [Related]
19. Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium-glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors. Lee HF; Chan YH; Chuang C; Li PR; Yeh YH; Hsiao FC; Peng JR; See LC Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):301-310. PubMed ID: 36639127 [TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real-world data analysis. Takahashi H; Asakawa K; Kosakai Y; Lee T; Rokuda M Diabetes Obes Metab; 2024 Mar; 26(3):997-1007. PubMed ID: 38086547 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]